Comparative epidemiology of gastric cancer between Japan and China

Table 2 Summary of findings on the associations between H. pylori carriage and risk of gastric cancer in prospective studies from Japan and China

Author[Ref.], yr	Country	Study design	Case patients /control subjects	Seroprevalence of H. pylori in cases vs controls (%)	ELISA kit used for measuring seroprevalence of H. pylori	OR (95% CI)
Watanabe et al[32], 1997	Japan	Nested case-control study	45/225	91.1 vs 75.6	Pirikaplate G Helicobacter enzyme immunoassay (Fujirebio Inc., Tokyo)	3.4 (1.2-9.9)
Sasazuki et al[35], 2006	Japan	Nested case-control study	511/511	93.5 vs 74.5	E Plate, produced by Eiken Kagaku Co.Ltd., Tokyo	5.1 (3.2-8.0)
Yamagata et al[33], 2000	Japan	Cohort study	1070 men and 1532 women at baseline	71.5 among men vs 62.4 among women	HM-CAP, Enteric Products Inc, Westbury, NY	Men: RR = 2.9 (1.1-7.4)
						Women: RR = 1.0 (0.3-3.0)
Yatsuya et al[34], 2004	Japan	Nested case-control study	202/394	88.6 vs 79.2	HM-CAP, Enteric Products Inc, Westbury, NY	Men: 1.7 (0.5-5.1) Women: 5.1 (1.6-16.5)
Yuan et al[38], 1999	China	Nested case-control study	188/548	86 vs 85	Locally Developed and Validated Assay	1.8 (1.1-3.1), but 3.7 (1.5-9.3) for subjects followed for 5 or more years
Limburg et al[39], 2001	China	Nested case-control study	181/192	62.0 vs 52.0	Antibodies to the whole cell antigen	1.6 (1.1-2.5)
Kamangar et al[12], 2007	China	Case-cohort study	Cardia 582/992 Noncardia 343/992	Cardia 81.0 vs 73.0 Noncardia	IgG antibodies to whole-cell antigen	Cardia 1.6 (1.3-2.1) Noncardia 1.6 (1.2-2.1)
				80.0 vs 73.0

OR: Odds ratio; RR: Relative risk; CI: Confidence interval.